Author: Eyben Finn Edler von
Publisher: Informa Healthcare
ISSN: 1040-8363
Source: Critical Reviews in Clinical Laboratory Sciences, Vol.40, Iss.4, 2003-07, pp. : 377-427
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The International Germ Cell Consensus Classification (IGCCC) of testicular germ cell tumors (TGCT) in 1997 included three serum tumor markers, serum lactate dehydrogenase catalytic concentration (S-LD), serum alpha fetoprotein concentration (S-AFP), and serum human chorionic gonadotropin concentration (S-hCG). The recommendation should be implemented for all patients with TGCT and is also useful for patients with ovarian and extragonadal germ cell tumors. A fourth serum tumor marker for TGCT, S-LD isoenzyme 1 (S-LD-1), is also relevant for TGCT. Patients with seminoma have a raised S-LD-1 more often than a raised S-AFP and S-hCG, whereas patients with nonseminoma have a raised S-AFP more often than a raised S-LD-1 and S-hCG. A new model combining IGCCC and S-LD-1 predicts survival better than previous staging systems. LD-1 is related to a characteristic chromosomal abnormality in all types of TGCT, a high copy number of chromosome 12p. In contrast, AFP and hCG are found mainly in nonseminomatous germ cell tumors and they related to the histologic differentiation of the tumors. The different biologic background for the serum tumor markers may contribute to the difference in their clinical behavior.
Related content
Ifosfamide in Germ Cell Tumors
Oncology, Vol. 65, Iss. 2, 2003-11 ,pp. :
Management of Germ Cell Tumors in Children: Approaches to Cure
Oncology Research and Treatment, Vol. 25, Iss. 1, 2002-03 ,pp. :
Sunitinib in Patients with Cisplatin-Refractory Germ Cell Tumors
Oncology Research and Treatment, Vol. 35, Iss. 7-8, 2012-07 ,pp. :